Source:http://linkedlifedata.com/resource/pubmed/id/19421175
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
12
|
| pubmed:dateCreated |
2009-12-23
|
| pubmed:abstractText |
We retrospectively analyzed the characteristics of 16 consecutive pediatric patients who received one or more G-CSF-mobilized donor lymphocyte infusions (DLI) following a T-cell-depleted haplocompatible hematopoietic SCT (HSCT) to enhance immune recovery and/or treat an infection. The median time from HSCT to administration of first DLI was 12 weeks and the median dose of DLI administered was 3 x 10(4)/kg (range, 2.5-6 x 10(4)/kg). The incidence of Grade I-II acute GVHD was 19% (95% confidence interval (CI), 6-44%), and there were no cases of Grade III-IV acute GVHD. Chronic GVHD developed in 13% (95% CI, 2-37%) of patients. In surviving patients who did not undergo a second stem cell infusion, T-cell numbers and function increased to a protective level in a median of 3 months (range, 2-12.5 months) following the first DLI administration. In patients given DLI for treatment of an infection, 75% (95% CI, 46-92%) cleared their infection after a median of 9 weeks (range, 1-27 weeks). In patients with CMV infection, the development of CMV-specific T cells was observed following DLI. The 1-year overall survival following haplocompatible DLI was 71% (95% CI, 59-83%), with a median follow-up of 16 months from the first DLI.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Dec
|
| pubmed:issn |
1476-5365
|
| pubmed:author | |
| pubmed:issnType |
Electronic
|
| pubmed:volume |
44
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
805-12
|
| pubmed:meshHeading |
pubmed-meshheading:19421175-Acute Disease,
pubmed-meshheading:19421175-Adolescent,
pubmed-meshheading:19421175-Adult,
pubmed-meshheading:19421175-Blood Donors,
pubmed-meshheading:19421175-Child,
pubmed-meshheading:19421175-Child, Preschool,
pubmed-meshheading:19421175-Chronic Disease,
pubmed-meshheading:19421175-Cytomegalovirus,
pubmed-meshheading:19421175-Cytomegalovirus Infections,
pubmed-meshheading:19421175-Disease-Free Survival,
pubmed-meshheading:19421175-Female,
pubmed-meshheading:19421175-Graft vs Host Disease,
pubmed-meshheading:19421175-Haplotypes,
pubmed-meshheading:19421175-Hematologic Neoplasms,
pubmed-meshheading:19421175-Hematopoietic Stem Cell Transplantation,
pubmed-meshheading:19421175-Humans,
pubmed-meshheading:19421175-Infant,
pubmed-meshheading:19421175-Lymphocyte Transfusion,
pubmed-meshheading:19421175-Male,
pubmed-meshheading:19421175-Recovery of Function,
pubmed-meshheading:19421175-Retrospective Studies,
pubmed-meshheading:19421175-Severe Combined Immunodeficiency,
pubmed-meshheading:19421175-Survival Rate,
pubmed-meshheading:19421175-Time Factors,
pubmed-meshheading:19421175-Transplantation, Homologous
|
| pubmed:year |
2009
|
| pubmed:articleTitle |
Clinical and immunologic outcomes following haplocompatible donor lymphocyte infusions.
|
| pubmed:affiliation |
UCSF Children's Hospital, University of California, San Francisco, USA. dvorakc@peds.ucsf.edu
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Multicenter Study
|